Clinical Trial Update: Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients. [Phase 4]

View source ↗

Summary

A Phase 4 pharmacogenetic study of CellCept (mycophenolate mofetil) in kidney transplant patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Kidney Transplantation | Phase 4 | Status: COMPLETED